Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018 is a new market research publication announced by Reportstack. Non-Hodgkin lymphoma (NHL) is a condition of the human body leading to the production of abnormal lymphocytes. In normal circumstances, the lymphocytes grow and die. However, in NHL they do not die; instead they grow and further divide. NHL can begin either in the T-cells or B-cells, though mostly it begins in the B-cells. The location of NHL is generally in the lymph nodes, but it can also spread to the body’s lymphatic system. It has many symptoms, of which swelling in the lymph nodes, abdominal pain, chest pain, cough, fever, fatigue, and night sweats are the most prominent. The causes of this disease are still unknown to scientists. NHL is linked with risk factors such as the overuse of immunosuppressant drugs, viruses such as HIV or Epstein-Barr, and bacteria such as Helicobacter pylori. NHL can be diagnosed by urine tests, physical examination for the enlargement of the lymph nodes, imaging tests (scans) such as magnetic resonance imaging (MRI) or computerized tomography (CT), and biopsy tests.
The analysts forecast the Global Non-Hodgkin Lymphoma Therapeutics market will grow at a CAGR of 7.03 percent over the period 2014-2018.This report covers the present scenario and the growth prospects of the Global Non-Hodgkin Lymphoma Therapeutics market for the period 2014-2018. The Global Non-Hodgkin Lymphoma Therapeutics market will observe a high growth in the forecast period. It is due to the availability of the biosimilars at a reduced price across the NHL market. This will be mainly due to the growth of the drug Rituxan in the global market. Apart from that, the market will also grow as a result of the improved diagnostic techniques to detect NHL. Besides, the increase in public awareness about NHL and robust drug pipeline for the treatment of NHL are the major influencers in the growth of the Global Non-Hodgkin Lymphoma Therapeutics market.
The report Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Non-Hodgkin Lymphoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
Americas
EMEA
APAC
The analysts forecast the Global Non-Hodgkin Lymphoma Therapeutics market will grow at a CAGR of 7.03 percent over the period 2014-2018.This report covers the present scenario and the growth prospects of the Global Non-Hodgkin Lymphoma Therapeutics market for the period 2014-2018. The Global Non-Hodgkin Lymphoma Therapeutics market will observe a high growth in the forecast period. It is due to the availability of the biosimilars at a reduced price across the NHL market. This will be mainly due to the growth of the drug Rituxan in the global market. Apart from that, the market will also grow as a result of the improved diagnostic techniques to detect NHL. Besides, the increase in public awareness about NHL and robust drug pipeline for the treatment of NHL are the major influencers in the growth of the Global Non-Hodgkin Lymphoma Therapeutics market.
The report Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Non-Hodgkin Lymphoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
Americas
EMEA
APAC
Key Vendors
Bristol Myers Squibb Co.
Celgene Corp.
Eli Lilly and Co.
F. Hoffman La-Roche Ltd.
GlaxoSmithKline plc
Bristol Myers Squibb Co.
Celgene Corp.
Eli Lilly and Co.
F. Hoffman La-Roche Ltd.
GlaxoSmithKline plc
Other Prominent Vendors
Accredo Health Group Inc.
Baxter International Inc.
Bayer AG
Cephalon Inc.
Eisai Pharmaceuticals Inc.
Genelabs Technologies Inc.
Hospira Inc.
Johnson & Johnson
Merck & Co. Inc.
Millenium Pharmaceuticals Inc.
Pacira Pharmaceuticals Inc.
Pfizer Inc.
Sanofi SA
Teva Pharmaceuticals Inc.
Accredo Health Group Inc.
Baxter International Inc.
Bayer AG
Cephalon Inc.
Eisai Pharmaceuticals Inc.
Genelabs Technologies Inc.
Hospira Inc.
Johnson & Johnson
Merck & Co. Inc.
Millenium Pharmaceuticals Inc.
Pacira Pharmaceuticals Inc.
Pfizer Inc.
Sanofi SA
Teva Pharmaceuticals Inc.
Key Market Driver
Availability of Biosimilars at a Reduced Price.
For a full, detailed list, view our report.
Availability of Biosimilars at a Reduced Price.
For a full, detailed list, view our report.
Key Market Challenge
High Cost of NHL Drugs.
For a full, detailed list, view our report.
High Cost of NHL Drugs.
For a full, detailed list, view our report.
Key Market Trend
Dominance of NHL Market by Biologics.
For a full, detailed list, view our report.
Dominance of NHL Market by Biologics.
For a full, detailed list, view our report.
Key Questions Answered in this Report
What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
To view the table of contents and know more details please visit Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018.
No comments:
Post a Comment